D3I4AD
Diagnostic and Drug Discovery Initiative for Alzheimer’s Disease
| Coordinatore | THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 2˙208˙897 € |
| EC contributo | 2˙208˙897 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-IAPP |
| Funding Scheme | MC-IAPP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-10-01 - 2018-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
UK (SHEFFIELD) | coordinator | 1˙009˙134.94 |
| 2 |
BIOFORDRUG SRL
Organization address
address: VIA EDOARDO ORABONA 4 DIP FARMACO CHIMICO UNIV BARI contact info |
IT (BARI) | participant | 449˙415.60 |
| 3 |
FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA
Organization address
address: CAMPO GRANDE C5 PISO 3 contact info |
PT (LISBOA) | participant | 399˙591.50 |
| 4 |
Eli Lilly and Company Limited
Organization address
address: "Lilly House, Priestley Road" contact info |
UK (Basingstoke) | participant | 290˙164.16 |
| 5 |
AMORFIX LIFE SCIENCES LTD
Organization address
address: AMERICAN DRIVE 3403 contact info |
CA (MISSISSAUGA ON) | participant | 60˙591.75 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Alzheimer’s disease (AD) is the major cause of dementia which has no cure at the moment. The overall aim of the work described in this proposal is to create a long-term strategic partnership between Sheffield University (UK), Lisbon University (Portugal), Eli Lilly (UK) and Biofordrug (Italy) in order to develop chemical biology tools for better understanding the role of PrPC in AD and harnessing this understanding to develop novel chemical entities for diagnostic and therapeutics applications.
The D3i4AD project brings together a consortium of groups with internationally-leading expertise from academia and industries in chemistry, molecular design and modelling, biochemistry, diagnostic and drug development. Our proposed programme will lead to major increases in the knowledge and capacity of all consortium members, achieved through significant intersectoral exchange of personnel between the partners over the duration of the project (total 134 person months) and through temporary recruitment of 5 new experienced researchers (total 114 person months). The project will thus underpin a substantial programme of intersectoral knowledge transfer and research training and lead to significant innovation and advances in several areas of basic research as well as diagnostics and therapeutics development. These activities will strongly enhance EU standing and international competitiveness in this extremely challenging and increasingly important technological area.'